Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Atezolizumab in Recurrent/Metastatic ESCC
NCT05007613Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, atezolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Taiwan University Hospital. Started Jun 2021; status: completed.
02
Drugs
cabozantinibatezolizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05007613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007613.